Similarly, we recently demonstrated that treatment with SPHK inhibitors significantly reduced cell proliferation, angiogenesis, and invasion, and increased apoptosis in ovarian cancer cells [16]. This evidence concerns the gene SPHK1 and ovarian carcinoma.